Nautilus Biotechnology, Inc. - Common Stock (NAUT)
0.9576
-0.0424 (-4.24%)
Nautilus Biotechnology Inc is a pioneering company focused on advancing the field of proteomics, which involves the large-scale study of proteins and their functions within biological systems
By leveraging cutting-edge technologies, Nautilus aims to provide researchers and healthcare professionals with innovative tools and solutions to gain deeper insights into protein behavior, interactions, and modifications. Their mission is to facilitate discoveries in various areas, including drug development, disease research, and personalized medicine, ultimately contributing to improved health outcomes and scientific knowledge.
U.S. stocks traded down this morning, with the Nasdaq Composite falling more than 101 points on Friday. Here are some big stocks recording gains in today’s session.
U.S. stocks traded down this morning with the Nasdaq Composite falling more than 101 points on Friday. The Dow traded down 0.23% to 34,396.96 while the NASDAQ fell 0.91% to 13,196.22. The S&P 500 also fell, dropping 0.45% to 4,350.51.
Nautilus Biotechnology (NASDAQ:NAUT) reported its Q3 earnings results on Tuesday, November 1, 2022 at 06:05 AM. Here's what investors need to know about the announcement.
Nautilus Biotechnology (NASDAQ:NAUT) reported its Q2 earnings results on Tuesday, August 2, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Gainers Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE) shares climbed 422% to $0.5572 after the company announced acquisition of Spyre Therapeutics and concurrent oversubscribed $210 million private investment positions.
The Dow Jones dropped more than 600 points on Monday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Gainers GigaCloud Technology Inc (NASDAQ: GCT) shares jumped 206% to close at $48.01 on Friday on continued volatility following the company's IPO on Thursday.
U.S. stock futures traded slightly higher this morning on Tuesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Nautilus Biotechnology (NASDAQ:NAUT) is set to give its latest quarterly earnings report on Tuesday, 2022-08-02. Here's what investors need to know before the announcement. Analysts estimate that Nautilus Biotechnology will report an earnings per share (EPS) of $-0.17.
